Join our CEO as he presents Cycuria Therapeutics‘ latest advancements in oncology innovation at the upcoming BIO-Europe conference in Vienna .
📍 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗩𝗶𝗲𝗻𝗻𝗮
🗓️ 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗡𝗼𝘃 𝟱 | 𝟭𝟬:𝟯𝟬 𝗔𝗠 | Wow
We’re proud to share that 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost , Scientific Founder of Cycuria Therapeutics , is featured in Drug Target Review discussing innovative strategies
Our CEO & Co-Founder, Nisit Khandelwal, joined host Jim Cornall on the 𝗕𝗮𝘀𝗲-𝘁𝗼-𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 to discuss Cycuria Therapeutics’ approach to treating some of the
Editor’s summary Relapse of acute myeloid leukemia (AML) is driven by populations of leukemic stem or progenitor cells (LSCs), which are resistant to chemotherapy. Here,
The study, led by Cycuria’s scientific founder, Prof. Dr. Philipp Jost , a clinician-scientist, and his research team, describes a natural tumor-suppressing mechanism mediated by
At Cycuria, we are dedicated to developing novel cytokine-based therapies to dramatically improve outcomes for patients living with cancer, offering hope where traditional treatments have fallen short.